1. Genentech wants to double its San Francisco footprint — Biotechs with the biggest cash piles — Purdue Pharma wants to pay bonuses even under bankruptcy proceedings — See more on our front page news

    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Sinking Ship

Discussion in 'BioDelivery Sciences' started by anonymous, Apr 23, 2019 at 10:32 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Here’s a great idea to save this sinking ship!!!

    The Problem:
    We’re not making goal
    Sales are eroding
    Stock price is dropping

    The Solution:
    Increase everyone’s goal 150%

    That’s going to solve everything!!! — said no competent sales leadership team ever
  2. anonymous

    anonymous Guest

    Sounds logical
  3. anonymous

    anonymous Guest

    The streets are talking and the streets are saying their goal is to sell the company. They won’t in-license Belbuca to potential suitors. The potential suitors have been told they must buy the entire company if they want Belbuca.
  4. anonymous

    anonymous Guest

    No one is interested in buying the company. They don’t want the management team or sales force or the three other products. They only want Belbuca (.)
  5. anonymous

    anonymous Guest

    Those companies obviously did their homework on BDSI. Does this mean BDSI has always been for sale?!
  6. anonymous

    anonymous Guest